Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Payables (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Payables data on record, last reported at $16.3 million in Q3 2025.

  • For Q3 2025, Payables rose 9.32% year-over-year to $16.3 million; the TTM value through Sep 2025 reached $16.3 million, up 9.32%, while the annual FY2024 figure was $16.0 million, 17.11% up from the prior year.
  • Payables reached $16.3 million in Q3 2025 per BTAI's latest filing, down from $16.7 million in the prior quarter.
  • Across five years, Payables topped out at $17.2 million in Q1 2024 and bottomed at $5.1 million in Q1 2022.
  • Average Payables over 4 years is $12.0 million, with a median of $13.3 million recorded in 2024.
  • Peak YoY movement for Payables: skyrocketed 122.42% in 2024, then dropped 10.28% in 2025.
  • A 4-year view of Payables shows it stood at $10.2 million in 2022, then skyrocketed by 33.5% to $13.7 million in 2023, then rose by 17.11% to $16.0 million in 2024, then rose by 1.79% to $16.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $16.3 million in Q3 2025, $16.7 million in Q2 2025, and $15.4 million in Q1 2025.